Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
CANDESARTAN CILEXETIL HYDROCHLOROTHIAZIDE
Clonmel Healthcare Ltd
8/12.5 Milligram
Tablets
2011-10-21
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Candist Plus 8 mg/12.5 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One Candist Plus 8 mg/12.5 mg tablet contains 8 mg candesartan cilexetil and 12.5 mg hydrochlorothiazide. Each tablet contains 117.30 mg lactose monohydrate. For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Tablet. Candist Plus 8 mg/12.5 mg tablets are white, biconvex tablets with a score line on one side and an embossing CH8 on the same side. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Candist Plus is indicated for the: • Treatment of essential hypertension in adult patients whose blood pressure is not optimally controlled with candesartan cilexetil or hydrochlorothiazide monotherapy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _POSOLOGY_ The recommended dose of Candist Plus is one tablet once daily. Dose titration with the individual components (candesartan cilexetil and hydrochlorothiazide) is recommended. When clinically appropriate a direct change from monotherapy to Candist Plus may be considered. Dose titration of candesartan cilexetil is recommended when switching from hydrochlorothiazide monotherapy. Candist Plus may be administered in patients whose blood pressure is not optimally controlled with candesartan cilexetil or hydrochlorothiazide monotherapy or Candist Plus at lower doses. Most of the antihypertensive effect is usually attained within 4 weeks of initiation of treatment. _SPECIAL POPULATIONS_ _Elderly population_ No dose adjustment is necessary in elderly patients. _Patients with intravascular volume depletion_ Dose titration of candesartan cilexetil is recommended in patients at risk for hypotensi Read the complete document